AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$AMRZ

Sanche Jacques Wolf purchased $187K of AMRZ

Sanche Jacques Wolf purchased 4,150 shares of Amrize Ltd (AMRZ) at $45.02 ($0.19M total) on 2026-08-26.

Original reporting
SEC EDGAR · Sanche Jacques Wolf
Published Aug 26, 2026, 9:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AMRZ
Neutral
medium confidence
Mentioned
$AMRZ
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZNeutralLow
01

Why it matters

The director's purchase adds a modest amount to his holdings, indicating personal confidence but unlikely to move the stock.

02

Market read

A routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed yet.

Relevance 5/10Novelty 4/10Timing: same day filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$AMRZNeutralMedium confidence
Context

Director Sanche Jacques Wolf bought 4,150 shares at $45.02, totaling $186,833.

Expected impact

Minimal short‑term price movement expected.

Evidence & confidence

Purchase size is modest relative to float; typical for a director rebalancing holdings.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could be a subtle bullish signal if the company is undervalued.

Key entities

  • Director
    Sanche Jacques Wolf

    Director of Amrize Ltd who purchased shares.

  • Company
    Amrize Ltd

    Issuer of the shares purchased.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMRZ insider trading history →

Related articles

SEP 16
Low

Amrize (SWX:AMRZ) Reshuffles Building Envelope Leadership As Fair Value Stays In Focus

Amrize (SWX:AMRZ) appointed Mario Gross as President of its Building Envelope division following Jake Gosa's resignation. The company's shares trade at CHF32.07, down 15.3% over the past month and 28.5% over the last quarter. Analysts suggest a fair value of CHF46.66, citing potential earnings power and margin expansion from the ASPIRE synergy program. The P/E ratio is 17.3x, compared to an estimated fair ratio of 30.5x and a peer average of 48.6x.

simplywall.st2 min
SEP 2
High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

investing.com2 min
SEP 2
$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

investing.com2 min